Propanc Biopharma has authorized a $5 million share repurchase program as it advances its lead cancer therapy candidate, PRP, into a pivotal Phase 1b clinical trial targeting metastatic solid tumors. The company highlights recent scientific progress, partnerships, and FDA Orphan Drug Designation for pancreatic cancer, which grants seven years of market exclusivity post-approval. Management views this as a transformative phase and believes the stock is undervalued, using buybacks to increase shareholder value while maintaining financial flexibility. The repurchase program allows various methods of stock buyback but does not obligate the company to a set number of shares and can be modified or suspended anytime.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
